Neumora Therapeutics (NMRA) Current Assets (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Current Assets of $153.4 million for Q1 2026, down 39.8% year-over-year from $254.9 million in Q1 2025, and down 19.47% quarter-over-quarter from $190.5 million in Q4 2025.
Neumora Therapeutics (NMRA) Current Assets (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $153.4 million for Q1 2026.
- In Q1 2026, Current Assets fell 39.8% year-over-year to $153.4 million; the TTM figure through Mar 2026 stood at $153.4 million (down 39.8% YoY), while the FY2025 annual figure was $190.5 million, down 39.33% from the prior year.
- Current Assets for Q1 2026 stood at $153.4 million, down from $190.5 million in the prior quarter.
- The five-year high for Current Assets was $525.7 million in Q3 2023, with the low at $153.4 million in Q1 2026.
- The 5-year median for Current Assets is $331.3 million (2024), against an average of $324.5 million.
- The sharpest annual moves came in 2023 and 2025: Current Assets grew 23.28% in 2023, then sank 49.2% in 2025.
- Neumora Therapeutics' Current Assets stood at $388.0 million in 2022, then gained by 23.28% to $478.3 million in 2023, then slumped by 34.34% to $314.1 million in 2024, then slumped by 39.33% to $190.5 million in 2025, then dropped by 19.47% to $153.4 million in 2026.
- Business Quant data shows NMRA's Current Assets at $153.4 million in Q1 2026, $190.5 million in Q4 2025, and $177.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 153.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.43 Mn |
| Dec 31, 2025 | 190.54 Mn |
| Sep 30, 2025 | 177.08 Mn |
| Jun 30, 2025 | 222.91 Mn |
| Mar 31, 2025 | 254.87 Mn |
| Dec 31, 2024 | 314.06 Mn |
| Sep 30, 2024 | 348.61 Mn |
| Jun 30, 2024 | 398.32 Mn |
| Mar 31, 2024 | 442.79 Mn |
| Dec 31, 2023 | 478.28 Mn |
| Sep 30, 2023 | 525.74 Mn |
| Dec 31, 2022 | 387.96 Mn |